Abstract 231P
Background
Pembrolizumab monotherapy has shown antitumor activity and acceptable safety in patients with mCRPC previously treated with a next-generation hormonal agent (NHA) and docetaxel.
Methods
The KEYNOTE-199 phase II study (NCT02787005) enrolled patients with RECIST-measurable PD-L1+ disease, RECIST-measurable PD-L1− disease, and bone-predominant disease irrespective of PD-L1 status in C1, C2, and C3, respectively. Patients had prior treatment with ≥1 NHA and 1 or 2 chemotherapies, including docetaxel, and received pembrolizumab 200 mg Q3W for 35 cycles or until progression/toxicity. The primary end point was ORR per RECIST v1.1 by blinded independent central review. Key secondary end points were time to PSA progression, DCR, PSA response rate, rPFS, OS, DOR, and safety.
Results
In total, 258 patients were treated (C1: 133; C2: 67; C3: 58), of whom 6 completed therapy (C1: 4; C3: 2). The median (range) time from enrollment to data cutoff was 31.3 mo (26.7-34.7), 30.6 mo (28.0-34.1), and 32.6 mo (27.4-34.4) in C1, C2, and C3, respectively. In patients with measurable disease, ORR (95% CI) was 6% (2.6-11.5) in C1 and 3% (0.4-10.4) in C2, and 6 of 10 responders experienced DOR ≥18 mo (Table). Median time to PSA progression was 4 mo regardless of cohort (Table). Grade ≥3 treatment-related AEs (TRAEs) occurred in 16%, 15%, and 17% of patients in C1, C2, and C3, respectively (1 death in each cohort from a TRAE [C1: sepsis; C2: unknown; C3: immune-related pneumonitis]). Table: 231P
Efficacy outcomes
Cohort 1 Measurable, PD-L1+ n = 133 | Cohort 2 Measurable, PD-L1− n = 67 | Cohort 3 Bone Predominant n = 58 | |
ORR per RECIST v1.1 per BICR, measurable disease, n/N (%) | 8/133 (6) | 2/67 (3) | – |
CR, n/N (%) | 3/133 (2) | 0 | – |
PR, n/N (%) | 5/133 (4) | 2/67 (3) | – |
DCR (CR + PR + SD or non-CR/non-PD ≥6 mo), n/N (%) | 14/133 (11) | 4/67 (6) | 12/58 (21) |
PSA response rate,a pts w/baseline PSA, n/N (%) | 8/124 (6) | 5/61 (8) | 1/58 (2) |
Median time to PSA progression, mo (95% CI) | 4 (4-4) | 4 (4-6) | 4 (4-4) |
Median rPFS per PCWG3-modified RECIST, mo (95% CI) | 2 (2-2) | 2 (2-3) | 4 (2-4) |
Median OS, mo (95% CI) | 10 (6-12) | 8 (6-10) | 14 (11-18) |
OS at 24 mo, % | 22 | 16 | 21 |
a≥50% decrease from baseline.
Conclusions
In 3 cohorts of docetaxel and NHA-pretreated patients with RECIST-measurable or bone-predominant mCRPC, pembrolizumab monotherapy led to promising antitumor activity and disease control and was well tolerated. There was durable antitumor activity and disease control, with survival up to 24 mo.
Clinical trial identification
NCT02787005, June 1, 2016.
Editorial acknowledgement
Medical writing and/or editorial assistance was provided by Matthew Grzywacz, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Legal entity responsible for the study
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Funding
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Disclosure
J.C.H. Goh: Shareholder/Stockholder/Stock options: Immutep Ltd.; Honoraria (self): MSD; Advisory/Consultancy: AstraZeneca, Tesaro, BMS; Speaker Bureau/Expert testimony: Ipsen; Travel/Accommodation/Expenses: AstraZeneca, Astellas. J.M. Piulats: Advisory/Consultancy: Roche, Novartis, Jansen, Astellas, Bayer, Sanofy-Genzyme, MSD, BMS, Merk-Serono, Clovis, AstraZeneca, Beigene, VCN Biotech; Research grant/Funding (self): Roche, Jansen, Astellas, MSD, BMS, Merk-Serono, AstraZeneca, Beigene, VCN Biotech; Travel/Accommodation/Expenses: Roche, Astellas, Jansen. M. Gross-Goupil: Honoraria (self): Ipsen, Janssen, Astellas; Advisory/Consultancy: Astellas, Janssen, Ipsen, MSD; Research grant/Funding (self): MSD, BMS, Janssen, AstraZeneca, Pfizer, Roche; Travel/Accommodation/Expenses: Amgen, MSD, Roche, Pfizer, Sanofi. U.N. Vaishampayan: Advisory/Consultancy, Research grant/Funding (institution): Merck & Co., Inc. R. de Wit: Advisory/Consultancy, Speaker Bureau/Expert testimony: Merck, Sanofi, Roche, Janssen, Clovis. T.V. Alanko: Honoraria (institution): Eli Lilly, Roche; Advisory/Consultancy: Bayer, BMS, Celgene, Eli Lilly, MSD, Nordic Drugs, Roche, Shire; Speaker Bureau/Expert testimony: Bayer, Servier; Travel/Accommodation/Expenses: BMS, Celgene, MSD, Roche, Shire. S. Fukasawa: Speaker Bureau/Expert testimony: Pfizer, Bristol-Myers Squibb, Ono Pharmaceutical, Janssen Pharmaceutical. S. Feyerabend: Advisory/Consultancy: AstraZeneca, Bayer; Travel/Accommodation/Expenses: Janssen. R. Berger: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: MSD, BMS, AZ. H. Wu: Shareholder/Stockholder/Stock options, Full/Part-time employment: Merck & Co., Inc. J. Kim: Shareholder/Stockholder/Stock options, Full/Part-time employment: Merck & Co., Inc. C. Schloss: Shareholder/Stockholder/Stock options, Full/Part-time employment: Merck & Co., Inc. J.S. de Bono: Advisory/Consultancy: AstraZeneca, Sanofi, Astellas Pharma, Pfizer, Genentech/Roche, Janssen Oncology, Menarini Silicon Biosystems, Daiichi Sankyo, Sierra Oncology, Bayer, Merck Sharp & Dohme, Merck Serono, Boehringer Ingelheim, Celgene, Taiho Pharmaceuticals, Genmab, SlasoSmi; Research grant/Funding (institution): AstraZeneca, Genentech, Sanofi, Taiho Pharmaceuticals, Daiichi Sankyo, Merck Serono, Astex Pharmaceuticals, Merck Sharp & Dohme, Orion Pharma, GlaxoSmithKline, Cellcentric, Celgene, Sierra Oncology, Bayer, MedImmune, Medication, Terumo, Astellas Pharma, G. E.S. Antonarakis: Research grant/Funding (self): Janssen, Sanofi, Dendreon, AstraZeneca Clovis, Merck, JohnsonJohnson, Genentech, Novartis, Bristol-Myers Squibb, Eli Lilly, Tokai, Celgene; Advisory/Consultancy: Janssen, Astellas, Sanofi, Dendreon, Medivation, ESSA, AstraZeneca, Clovis, Merck, Eli Lilly, Amgen, Bayer, GlaxoSmithKline; Licensing/Royalties: Qiagen. All other authors have declared no conflicts of interest.
Resources from the same session
403P - Clinical profile, practice pattern and outcomes in ALK-positive lung cancer: Real-world data from India
Presenter: Akhil Kapoor
Session: e-Poster Display Session
404P - Financial toxicity in patients with advanced lung cancer treated with immunotherapy: Has it an effect on the clinical decision?
Presenter: Jia-Hui Weng
Session: e-Poster Display Session
405P - Promising efficacy as combination therapy of DFP-14323, protease inhibitor, with EGFR-TKI in patients with metastatic NSCLC harboring EGFR mutation
Presenter: Hiroshige Yoshioka
Session: e-Poster Display Session
406P - Anti-PD-1 versus anti-PD-L1 inhibitors in first-line therapy non-small-cell lung cancer: A systematic review and meta-analysis
Presenter: Angelo Brito
Session: e-Poster Display Session
407P - Integrating histologic and genomic characteristics to predict tumour mutation burden of early-stage non-small cell lung cancer
Presenter: Yuan Qiu
Session: e-Poster Display Session
408P - Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
Presenter: Julia Maevskaya
Session: e-Poster Display Session
409P - Effect of transdermal granisetron on prevention of nausea and vomiting during chemotherapy of lung cancer
Presenter: Haifeng Qin
Session: e-Poster Display Session
410P - Frequency and spectrum of primary resistance mechanism in Chinese ALK+ non-small cell lung cancer patients progressing on crizotinib: A multicenter study
Presenter: Wen-xian Wang
Session: e-Poster Display Session
411P - Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation
Presenter: Yoshihiko Taniguchi
Session: e-Poster Display Session
412P - Treatment patterns and selection criteria for advanced non-small cell lung cancer (NSCLC) patients unfit for platinum-based first-line therapy: Results of the MOON-OSS observational trial
Presenter: Andrea Camerini
Session: e-Poster Display Session